Author:
Uchida Mayako,Nakamura Tsutomu,Hata Kojiro,Watanabe Hiroyuki,Mori Yasuo,Kato Koji,Kamezaki Kenjiro,Takenaka Katsuto,Shiratsuchi Motoaki,Hosohata Keiko,Miyamoto Toshihiro,Akashi Koichi
Funder
Start-up from the Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology (nursing)
Reference32 articles.
1. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482–94.
2. NCCN. Clinical Practice Guidelines in Oncology-Antiemesis-Version II. Available from:
https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
. Accessed 25 Dec 2017.
3. Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, Clark-Snow RA, Danso MA, Jordan K, Somerfield MR, Kris MG, American Society of Clinical O. Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol. 2016;34:381–6.
4. Oncology JSoC. JSCO Clinical Practice Guidelines 2015 for Antiemesis. Available from:
http://www.jsco-cpg.jp/item/29/index.html
. Accessed 25 Dec 2017.
5. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23:1289–94.